Regardless the expression of PD-L1 is remarkable in MET exon 14 NSCLC [140], and the immune checkpoint blockage strategy seems ineffective as monotherapy in patients with MET exon 14 NSCLC [141, 142]. This evidence concerns the gene MET and non-small cell lung carcinoma.